RESOURCES

  • NewsletterSeptember 3rd, 2025

    Focus on FAPI Newsletter – Fall 2025

  • [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
    PublicationsAugust 4th, 2025

    [68Ga]Ga-API-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial

  • 90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors
    PublicationsJuly 24th, 2025

    90 Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors

  • Early image acquisition 68Ga-FAPI-46-PET/CT in prone position is promising in the workup of rectosigmoid and anal carcinoma
    PublicationsJuly 16th, 2025

    Early image acquisition 68Ga-FAPI-46-PET/CT in prone position is promising in the workup of rectosigmoid and anal carcinoma 

  • Current State of FAP Targeting Radioligands in Oncology
    WebinarsJune 18th, 2025

    Current State of FAP Targeting Radioligands in Oncology

  • FAPI Newsletter Spring 2025
    NewsletterJune 9th, 2025

    Focus on FAPI Newsletter – Spring 2025

  • Liver fibrosis is a chronic fibrosing hepatic disorder following recurrent injury, characterized by the excessive accumulation of extracellular matrix.
    PublicationsJune 9th, 2025

    Efficacy of [68Ga]Ga-FAPI-PET as a non-invasive evaluation method of liver fibrosis

  • Comparison of [99mTc]Tc-FAPI SPECT/CT and [18F]FDG PET/CT as predictive biomarkers for immunotherapy response in gastrointestinal cancer
    PublicationsMay 14th, 2025

    Comparison of [99mTc]Tc-FAPI SPECT/CT and [18F]FDG PET/CT as predictive biomarkers for immunotherapy response in gastrointestinal cancer

  • SOFIE Biosciences opens PET Manufacturing Facility, expanding service in Illinois, Missouri, and Indiana
    NewsApril 1st, 2025

    SOFIE Biosciences opens PET Manufacturing Facility, expanding service in Illinois, Missouri, and Indiana

  • FAPI Post Winter 2025
    NewsletterMarch 13th, 2025

    Focus on FAPI Newsletter – Winter 2025

  • Spatial FAP Expression as Detected by 68 Ga-FAPI-46 Identifies Myofibroblasts Beyond the Infarct Scar After Reperfusion
    PublicationsMarch 3rd, 2025

    Spatial FAP Expression as Detected by 68 Ga-FAPI-46 Identifies Myofibroblasts Beyond the Infarct Scar After Reperfusion

  • Head-to-head comparison of 18F-FDG and 68Ga-FAPI PET/CT in common gynecological malignancies
    PublicationsFebruary 28th, 2025

    Head-to-head comparison of 18F-FDG and 68Ga-FAPI PET/CT in common gynecological malignancies

  • Discrimination between Inflammatory and Fibrotic Activity in Crohn's Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging
    PublicationsFebruary 8th, 2025

    Discrimination between Inflammatory and Fibrotic Activity in Crohn’s Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging

  • NewsJanuary 15th, 2025

    SOFIE network expands production of 18F-FAPI-74

  • FAPI Newsletter Summer 2024
    NewsletterDecember 12th, 2024

    Focus on FAPI Newsletter – Fall 2024

  • Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors
    PublicationsDecember 3rd, 2024

    Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

  • FAPI PET/CT, a Novel Tracer in Oncology
    WebinarsNovember 9th, 2024

    Imaging Cancer through the Stroma – FAPI PET/CT, a Novel Tracer in Oncology

  • FAPI-PET imaging & theranostics: A new era in targeting cancer and fibrotic diseases
    WebinarsNovember 7th, 2024

    FAPI-PET imaging & theranostics: A new era in targeting cancer and fibrotic diseases

  • Impact of fat intake on [18F]AIF-NOTA-FAPI-04 uptake in normal abdominal organs
    PublicationsNovember 7th, 2024

    Impact of fat intake on [18F]AIF-NOTA-FAPI-04 uptake in normal abdominal organs

  • Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models
    PublicationsOctober 28th, 2024

    Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models

  • FAPI Newsletter Summer 2024
    NewsletterSeptember 4th, 2024

    Focus on FAPI Newsletter – Summer 2024

  • 99mTc-HFAPi SPECT imaging predicts left ventricular remodeling after acute myocardial infarction
    PublicationsAugust 4th, 2024

    99mTc-HFAPi SPECT imaging predicts left ventricular remodeling after acute myocardial infarction

  • Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma
    PublicationsAugust 1st, 2024

    Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial

  • Current State of FAP Ligands for Diagnostic Use in Oncology
    PresentationsJune 14th, 2024

    Current State of FAP Ligands for Diagnostic Use in Oncology

  • FAPI Symposium Panel
    NewsJune 12th, 2024

    SOFIE and GE HealthCare SNMMI Symposium highlights FAP targeting

  • FAPI-46 Phase 2 clinical development updates
    PresentationsJune 9th, 2024

    [68Ga]FAPI-46 Phase 2 clinical development updates

  • FAPI Spring 2024 Newsletter
    NewsletterJune 3rd, 2024

    Focus on FAPI Newsletter – Spring 2024

  • The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review
    PublicationsMay 31st, 2024

    The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review

  • NewsMay 23rd, 2024

    [18F]FAPI-74 serving as complementary diagnostic in Avacta Phase 1 trial

  • [68Ga]Ga-FAPI-46 PET/CT for penile cancer - a feasibility study
    PublicationsMay 18th, 2024

    [68Ga]Ga-FAPI-46 PET/CT for penile cancer – a feasibility study

  • 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
    PublicationsMay 9th, 2024

    68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

  • A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers
    PublicationsApril 18th, 2024

    A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers

  • PublicationsApril 4th, 2024

    Highlights of the 36th EANM Annual Congress 2023, from hometown Vienna, Austria: “A SYMPHONY OF SCIENCE”

  • FAPI Newsletter Winter 2024
    NewsletterMarch 12th, 2024

    Focus on FAPI Newsletter – Winter 2024

  • PublicationsFebruary 18th, 2024

    Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor

  • PublicationsFebruary 12th, 2024

    18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma

  • FAPI Newsletter Summer 2023
    NewsletterDecember 6th, 2023

    Focus on FAPI Newsletter – Fall 2023

  • PublicationsDecember 1st, 2023

    68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study

  • Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol
    PublicationsNovember 27th, 2023

    Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol

  • 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
    PublicationsNovember 10th, 2023

    68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study

  • 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma
    PublicationsNovember 6th, 2023

    68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial

  • Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT
    PublicationsOctober 20th, 2023

    Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT

  • NewsOctober 11th, 2023

    SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

  • FAPI Newsletter Summer 2023
    NewsletterAugust 29th, 2023

    Focus on FAPI Newsletter – Summer 2023

  • Head-to-Head Intra-Individual Comparison of FAP
    PublicationsAugust 29th, 2023

    Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study

  • Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
    PublicationsAugust 29th, 2023

    Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib

  • Diagnostic Performance of Positron Emission Tomography with FAP
    PublicationsAugust 29th, 2023

    Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis

  • Fibroblast Activation Protein (FAP) – a target for Imaging and Therapy
    PresentationsJuly 25th, 2023

    Fibroblast Activation Protein (FAP) – a target for Imaging and Therapy

  • NewsJuly 7th, 2023

    FAP symposium another success at 2023 SNMMI meeting

  • RLS and SOFIE Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients
    NewsJune 21st, 2023

    RLS and SOFIE Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients

  • NewsletterJune 12th, 2023

    Focus on FAPI Newsletter – Spring 2023

  • NewsJune 6th, 2023

    SOFIE partners with BAMF Health, diversifying sites for Phase II [68Ga]FAPI-46 study

  • NewsMay 12th, 2023

    First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial

  • FAPI Theragnostics
    PresentationsMarch 31st, 2023

    FAPI Theragnostics

  • PresentationsMarch 14th, 2023

    Fibroblast Activation Protein (FAP) Inhibitors as Biomarkers in Oncology, Fibrotic Disease, and Cardiovascular Disease

  • FAPI Newsletter Winter 2023
    NewsletterFebruary 5th, 2023

    Focus on FAPI Newsletter – Winter 2023

  • FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease
    PublicationsFebruary 5th, 2023

    FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

  • Novel 68Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls
    PublicationsFebruary 5th, 2023

    Novel 68Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls

  • NewsJanuary 31st, 2023

    SOFIE and Mayo Clinic collaborate to secure $3M NIH grant for FAPI clinical trial

  • NewsJanuary 17th, 2023

    IND granted for FAP targeting therapeutic in SOFIE partnership

  • SOFIE granted IND for 18F-FAPI in Phase 2 study
    NewsNovember 29th, 2022

    SOFIE granted IND for 18F-FAPI in Phase 2 study

  • Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer
    PublicationsNovember 17th, 2022

    Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer

  • 3-time-point PET-analysis of FAPI-46 in a variety of cancers
    PublicationsNovember 10th, 2022

    3-time-point PET-analysis of FAPI-46 in a variety of cancers

  • FAPI Clinical Development Updates
    PresentationsNovember 5th, 2022

    FAPI Clinical Development Updates

  • FAPI Newsletter October 2022
    NewsletterOctober 31st, 2022

    Focus on FAPI Newsletter – October 2022

  • NewsOctober 31st, 2022

    SOFIE submits IND for [18F]-FAPI-74 in Phase 2 study of Gastrointestinal Cancers

  • Image First Patient Ga-FAPI
    NewsOctober 13th, 2022

    First Patient Imaged in SOFIE’s FAPI Phase II Trial

  • Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74
    PublicationsAugust 18th, 2022

    Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74

  • Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types
    PublicationsJuly 29th, 2022

    Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types

  • Current Status of Clinical Trials on FAP Targeted Radiopharmaceuticals
    PresentationsJuly 19th, 2022

    Current Status of Clinical Trials on FAP Targeted Radiopharmaceuticals

  • Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities
    PublicationsJuly 14th, 2022

    Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities

  • FAPI Awards
    NewsJune 30th, 2022

    FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting

  • FAPI Symposium
    NewsJune 22nd, 2022

    FAP session at Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting attracts packed audience

  • SOFIE FAPI Clinical Development Update
    PresentationsJune 12th, 2022

    SOFIE FAPI Clinical Development Update

  • FAP-Ligand PET Update
    PresentationsJune 12th, 2022

    FAP-Ligand PET Update ≠ Cancer

  • WebinarsJune 12th, 2022

    FAP Ligands for Imaging and Therapy

  • A promising target for radiopharmaceuticals
    WebinarsJune 8th, 2022

    Fibroblast Activation Protein (FAP) – A promising target for radiopharmaceuticals

  • PublicationsJune 1st, 2022

    Pitfalls and Common Findings in 68 Ga-FAPI PET: A Pictorial Analysis

  • PublicationsApril 11th, 2022

    Comparison of 68 Ga-FAPI PET/CT and 18 FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement

  • PublicationsApril 7th, 2022

    FAPI-PET Opens a New Window for Understanding of Immune-Mediated Inflammatory Diseases

  • PublicationsApril 1st, 2022

    Comparison of 68 Ga-FAPI and 18 F-FDG PET/CT in the Evaluation of Advanced Lung Cancer

  • PublicationsMarch 29th, 2022

    Head-to-head Intra-individual Comparison of [ 68 Ga]-FAPI and [ 18 F]-FDG PET/CT in Patients with Bladder Cancer

  • PublicationsMarch 24th, 2022

    Feasibility of [ 68 Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma

  • PublicationsFebruary 22nd, 2022

    Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

  • PublicationsJanuary 20th, 2022

    New Fully Automated Preparation of High Apparent Molar Activity 68 Ga-FAPI-46 on a Trasis AiO Platform

  • PublicationsJanuary 9th, 2022

    Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review

  • NewsNovember 10th, 2021

    SOFIE gets greenlight from US FDA to proceed to Phase II Pancreatic Cancer Study

  • FAPI
    PublicationsNovember 2nd, 2021

    FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

  • major milestone with the filing of an IND application to the FDA for a radiopharmaceutical targeting Fibroblast Activation Protein Inhibitor (FAPI)
    NewsOctober 12th, 2021

    SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging

  • Novartis and iTheranostics
    NewsMarch 30th, 2021

    SOFIE affiliate, iTheranostics, executes agreement for its promising library of Fibroblast Activation Protein (FAP) targeted theranostics

  • PublicationsFebruary 24th, 2021

    FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

  • 68 Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [ 18 F] FDG PET/CT
    PublicationsFebruary 24th, 2021

    68 Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [ 18 F] FDG PET/CT

  • Fibroblast Activation Protein–Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
    PublicationsFebruary 6th, 2021

    Fibroblast Activation Protein-Targeted PET/CT with 68 Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18 F-FDG PET/CT

  • [ 18 F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions
    PublicationsFebruary 2nd, 2021

    [ 18 F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions

  • Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer
    PublicationsFebruary 1st, 2021

    Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer

  • Targeting Fibroblast Activation Protein
    PublicationsDecember 6th, 2020

    Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18 F-Labeled FAP Inhibitor

  • Protein_FAP
    PublicationsNovember 5th, 2020

    Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging

  • Jubilant Radiopharma
    NewsNovember 4th, 2020

    SOFIE Biosciences Inc. (SOFIE) concludes $27.4m Series C Financing

  • Head and neck cancer
    PublicationsNovember 4th, 2020

    Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers?

  • liver
    PublicationsOctober 3rd, 2020

    68Ga-FAPI PET/CT in Assessment of Liver Nodules in a Cirrhotic Patient

  • hepatic cancer
    PublicationsAugust 10th, 2020

    [ 68 Ga]Ga-DOTA-FAPI-04 and [ 18 F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with hepatic cancer

  • cancer
    PublicationsJuly 29th, 2020

    Comparison of [ 68 Ga]Ga-DOTA-FAPI-04 and [ 18 F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer

  • Cholangiocellular Carcinoma
    PublicationsJuly 24th, 2020

    Comparison of 68Ga-FAPI and 18F-FDG PET/CT in a Patient With Cholangiocellular Carcinoma: A Case Report

  • 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation
    PublicationsJuly 10th, 2020

    68 Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation

  • Usefulness of [ 68 Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [ 18 F]FDG PET/CT findings
    PublicationsJune 25th, 2020

    Usefulness of [ 68 Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [ 18 F]FDG PET/CT findings

  • nanocrystals
    PublicationsMay 13th, 2020

    Pushing Absorption of Perovskite Nanocrystals into the Infrared

  • Esophageal-cancer
    PublicationsApril 24th, 2020

    [ 68 Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer

  • ABX and SOFIE
    NewsOctober 10th, 2019

    Sofie Biosciences Enters Strategic Collaboration For The Production And Distribution Of FAPI Precursors

  • FAPI PET
    NewsAugust 7th, 2019

    SOFIE’s IP Named FAPI Wins SNMMI 2019 Image of The Year

  • University Clinic Heidelberg
    NewsJune 21st, 2019

    SOFIE and University Clinic Heidelberg Sign License Agreement

CONTACT US

Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.